According to UPI, researchers have found a long-acting, injectable implant to show promise in the prevention and treatment of HIV in mice. The new protocol has subjects receive a continuous formulation of an antiretroviral medication called dolutegravir for nine months through an implantable device that can then be removed, rather than receiving a once-daily pill. The drug, which was approved for use in the United States in 2013, is sold under the brand name Tivicay.